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Abstract 
Background: Doxorubicin (DOX)-based chemotherapy for Hodgkin lymphoma (HL) yields excellent disease-free 
survival, but poses a substantial risk of subsequent left ventricular (LV) dysfunction and heart failure, typically with 
delayed onset. At the cellular level, this cardiotoxicity includes deranged cardiac glucose metabolism.
Methods: By reviewing the hospital records from January 2008 through December 2016, we selected HL patients 
meeting the following criteria: ≥ 18 year-old; first-line DOX-containing chemotherapy; no diabetes and apparent 
cardiovascular disease; 18-fluoro-deoxyglucose positron emission tomography (18FDG-PET) scans before treatment 
 (PETSTAGING), after 2 cycles  (PETINTERIM) and at the end of treatment  (PETEOT); at least one echocardiography ≥ 6 months 
after chemotherapy completion  (ECHOPOST). We then evaluated the changes in LV 18FDG standardized uptake values 
(SUV) during the course of DOX therapy, and the relationship between LV-SUV and LV ejection fraction (LVEF), as 
calculated from the LV diameters in the echocardiography reports with the Teicholz formula.
Results: Forty-three patients (35 ± 13 year-old, 58% males) were included in the study, with 26 (60%) also hav-
ing a baseline echocardiography available  (ECHOPRE). LV-SUV gradually increased from  PETSTAGING (log-transformed 
mean 0.20 ± 0.27) to  PETINTERIM (0.27 ± 0.35) to  PETEOT (0.30 ± 0.41; P for trend < 0.001).  ECHOPOST was performed 
22 ± 17 months after DOX chemotherapy. Mean LVEF was normal (68.8 ± 10.3%) and only three subjects (7%) faced 
a drop below the upper normal limit of 53%. However, when patients were categorized by median LV-SUV, LVEF at 
 ECHOPOST resulted significantly lower in those with LV-SUV above than below the median value at both  PETINTERIM 
(65.5 ± 11.8% vs. 71.9 ± 7.8%, P = 0.04) and  PETEOT (65.6 ± 12.2% vs. 72.2 ± 7.0%, P = 0.04). This was also the case when 
only patients with  ECHOPRE and  ECHOPOST were considered (LVEF at  ECHOPOST 64.7 ± 8.9% vs. 73.4 ± 7.6%, P = 0.01 
and 64.6 ± 9.3% vs. 73.5 ± 7.0%, P = 0.01 for those with LV-SUV above vs. below the median at  PETINTERIM and  PETEOT, 
respectively). Furthermore, the difference between LVEF at  ECHOPRE and  ECHOPOST was inversely correlated with LV-
SUV at  PETEOT (P < 0.01,  R2 = − 0.30).
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Background
Anthracyclines are the cornerstone of many life-saving 
treatments, and Hodgkin lymphoma (HL) is a paradigm 
of a curable malignancy also by virtue of anthracycline-
based chemotherapy regimens, with optimal treatment 
providing a 10-year disease-free survival exceeding 80% 
[1, 2]. Unfortunately, however, anthracyclines are cardio-
toxic [3].
Anthracycline cardiotoxicity may present as left ven-
tricular (LV) dysfunction and heart failure within months 
or few years after exposure to high cumulative doses of 
drug, especially in the case of pre-existing cardiovascu-
lar disease. Nonetheless, LV dysfunction and heart fail-
ure may also develop more insidiously, several years after 
treatment with only moderate doses of anthracyclines 
[4–6]. This type of cardiotoxicity is typically observed 
in patients who do not have cardiovascular risk factors 
or disorders at the time of chemotherapy, such as first-
line treated subjects with HL, for whom the incidence of 
anthracycline-related LV dysfunction may be as high as 
one in three treated patients [7].
Predicting late anthracycline cardiotoxicity is chal-
lenging. Both biomarkers and echocardiography with 
speckle tracking analysis or cardiac magnetic resonance 
imaging have been proposed to identify individuals who 
may require cardiac monitoring and may benefit from 
early cardioprotection with drugs such as beta-blockers 
and angiotensin converting enzyme inhibitors [8–11]. 
Yet, these tools are underused in clinical practice as 
they require additional exams for already overwhelmed 
patients, need expert personnel for appropriate interpre-
tation of the results and, in some cases, are expensive.
Whole-body 18-fluoro-deoxyglucose positron emis-
sion tomography (18FDG-PET) is recommended for HL 
staging [2, 12]. While the oncologist evaluates 18FDG 
uptake in the hematopoietic system, this exam may 
also offer unique information concerning the effects of 
anthracyclines on the heart. Impaired mitochondrial 
oxidative metabolism with heightened glycolytic flux 
is a major feature of anthracycline cardiotoxicity in 
experimental mouse models [13, 14]; since hexokinase, 
the rate-limiting enzyme of glycolysis, is also respon-
sible for phosphorylation and intracellular retention 
of 18FDG, it is expected that myocardial uptake of this 
tracer increases in response to anthracycline. In fact, 
previous studies demonstrated a change in LV 18FDG 
standardized uptake value (LV-SUV) during anthracy-
cline exposure [15] and it has been hypothesized that 
18FDG-PET might detect myocardial toxicity of anthra-
cycline very early [16]. Consistent with this literature, 
we recently found that 18FDG uptake increases in mice 
injected with the anthracycline, doxorubicin (DOX), 
as well as in patients receiving anthracycline-contain-
ing chemotherapy, with a direct correlation with a 
composite endpoint of subsequent cardiac alterations 
[17]. Here, we sought to expand these findings focus-
ing on LV ejection fraction (EF), because even minor 
decreases in this parameter were shown to predict clin-
ically relevant anthracycline cardiotoxicity [18].
Methods
Patient selection
This retrospective study included patients affected by 
HL and referred to the IRCCS San Martino Policlinic 
Hospital, Genova, Italy, between January 2008 and 
December 2016. According to the research mission of 
the hospital and as per approval by the local Institu-
tional Review Board, all subjects signed an informed 
consent allowing the utilization of their anonymized 
clinical data for scientific purposes.
By reviewing the medical records, eligible patients 
were identified based on the following criteria (Fig. 1): 
age ≥ 18  years; HL receiving first-line chemotherapy 
with DOX as part of the ABVD or BEACOPP protocols; 
at least three 18FDG-PET scans available, i.e. before 
treatment  (PETSTAGING), after 2 cycles  (PETINTERIM) and 
at the end of treatment  (PETEOT); no diabetes; no more 
than two major cardiovascular risk factors, no history 
of cardiac disease and normal ECG at baseline; and 
transthoracic echocardiography performed ≥ 6 months 
after DOX exposure  (ECHOPOST). Thus, by study 
design all subjects underwent an echocardiogram 6 or 
more months after chemotherapy completion. Some 
patients, however, received more than one post-treat-
ment echocardiogram: in this case, the most recent one 
was considered (i.e. closest to the time when the retro-
spective analysis was carried out). When available, data 
of a baseline echocardiographic evaluation  (ECHOPRE) 
were also taken into account.
Conclusions: DOX-containing chemotherapy causes an increase in cardiac 18FDG uptake, which is associated with a 
decline in LVEF. Future studies are warranted to understand the molecular basis and the potential clinical implications 
of this observation.
Keywords: Doxorubicin, Cardiotoxicity, 18FDG-PET, Left ventricular dysfunction, Heart failure
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Nuclear imaging
18FDG-PET/CT scans were performed using a 16-slice 
Biograph 16 PET/CT hybrid system (Siemens Medi-
cal Solutions). In accordance to standard clinical prac-
tice, each patient received an intravenous bolus of 
4.8–5.2 MBq/kg 18FDG. PET/CT acquisition started after 
60–75 min, during which subjects were recommended to 
drink water in order to increase the urinary clearance of 
the unbound 18FDG fraction. The body was scanned from 
vertex to mid-thigh in arms-up position. The emission 
scan lasted 120  s per bed position. PET raw data were 
reconstructed using ordered-subset expectation maximi-
zation (OSEM, 3 iterations; 16 subsets), and attenuation 
was corrected using the raw CT data. 16-detector-row 
helical CT was performed with non-diagnostic current 
and voltage settings (120  kV; 80  mA), a gantry rotation 
speed of 0.5  s, and a table speed of 24  mm per gantry 
rotation. The entire CT dataset was merged with the 
three-dimensional PET images using an integrated soft-
ware interface (Syngo; Siemens Medical Solutions).
Volumes of interest were manually drawn on the met-
abolically active LV myocardium and on a 2  cm-thick 
section of longissimus thoracis muscle at the level of 
12th vertebral body. When the LV was not clearly iden-
tifiable on PET images due to the low myocardial 18FDG 
uptake, hybrid PET/CT images were used to select the 
volume of interest. Next, the mean SUV within the 
LV and skeletal muscle (SM) volumes of interest were 
measured (LV-SUV and SM-SUV, respectively) and 
normalized for the circulating 18FDG concentration, as 
estimated by the mean SUV value in a volume of inter-
est drawn at the level of the inferior vena cava, in order 
to correct for the noise signal of the blood pool. The 
ratio between LV-SUV and SM-SUV was then calcu-
lated. These analyses were carried out by two nuclear 
medicine specialists with experience in 18FDG-PET and 
cardiac imaging, who were blinded to other data.
Echocardiography
All patients underwent standard transthoracic echocar-
diography. LVEF was measured by means of the Teicholz 
formula by two cardiologists, different from those who 
selected the study cases and blinded to clinical and 
nuclear medicine data. Although a LVEF value was writ-
ten in the echocardiography reports, this parameter was 
recalculated in order to have standardized and thereby 
comparable numbers.
PETSTAGING PETINTERIM PETEOT ECHOPOST
(ECHOPRE)
DOX 
starts
DOX 
2nd cycle
DOX
ends
≥6 months
overt cardiomyopathy
(LV dysfunction → LV 
dilation and heart failure)
altered myocardial metabolism
cardiomyocyte injury
(oxidative stress, DNA 
damage, mitochondrial
derangement)
Fig. 1 Study design and stages of anthracycline cardiotoxicity. A schematic of the timing of the 18FDG positron emission tomography (18FDG-PET) 
scans and echocardiograms taken into analysis is depicted in the upper panel, while the corresponding stages of anthracycline-related 
cardiotoxicity are presented in the lower part. DOX: doxorubicin-containing chemotherapy;  ECHOPRE: echocardiography at baseline (available only 
in a subgroup of patients);  ECHOPOST: echocardiography after completion of DOX chemotherapy;  PETSTAGING: 18FDG-PET before treatment;  PETINTERIM: 
18FDG-PET after 2 cycles of doxorubicin;  PETEOT: 18FDG-PET at the end of treatment; LV: left ventricular
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Statistical analysis
Statistical analysis was performed using the statistical 
package of R-software (ver. 3.4). Data are given as num-
ber (percentage of total), mean ± standard deviation or 
median (interquartile range). LV-SUV and SM-SUV val-
ues were normalized by logarithmical transformation. 
Comparisons were drawn by unpaired or paired Stu-
dent’s t-test or repeated measures ANOVA, as appropri-
ate, while the relationship between LVEF changes and 
LV-SUV was assessed by Pearson’s correlation test. The 
association between LVEF changes and LV-SUV was also 
examined in a linear regression model with age and DOX 
dose as covariates, since they can affect LV function. A P 
value < 0.05 was considered significant.
Results
Sixty-five patients were eligible during the study period, 
but 22 did not have  ECHOPOST, leaving a sample of 43 
subjects. For 26 of them (60%),  ECHOPRE was available.
The baseline characteristics of the 43 patients are sum-
marized in Table  1. Mean age was 35 ± 13  years, male 
gender was slightly predominant and the prevalence 
of cardiovascular risk factors was low. Consistent with 
the fact that diabetes was a cause of exclusion from the 
study, mean fasting plasma glucose was normal at base-
line (82 ± 9 mg/dL), and remained normal at  PETINTERIM 
(83 ± 10  mg/dL) and  PETEOT (86 ± 24  mg/dL). LVEF in 
the subgroup with  ECHOPRE was always within the nor-
mal range.
A significant progressive increase in LV-SUV was 
observed over DOX treatment (Fig.  2), and this trend 
was confirmed in the subgroup of patients with  ECHOPRE 
(data not shown). SM-SUV also increased during chemo-
therapy (Fig. 2), thus no significant change occurring in 
the ratio between LV-SUV and SM-SUV.
ECHOPOST was performed 22 ± 17 (range 6–76) 
months after DOX chemotherapy. LVEF dropped below 
the upper normal limit of 53% in 3 (7%) patients, who 
remained asymptomatic, and mean LVEF in  ECHOPOST 
was normal (68.8 ± 10.3%), as was LV end-diastolic 
diameter (LVEDD) (47.4 ± 5.1  mm). In the subgroup 
with both  ECHOPRE and  ECHOPOST, mean LVEF and 
LVEDD minimally and non-significantly changed from 
69.0 ± 9.3 to 70.3 ± 7.1% (P = 0.43) and from 47.2 ± 5.2 to 
46.9 ± 4.9 mm (P = 0.60), respectively.
However, when patients were categorized in high 
and low LV-SUV by LV-SUV median value, LVEF was 
significantly lower in those with high vs. low LV-SUV 
values at both  PETINTERIM and  PETEOT (Fig.  3). This 
was also the case when only subjects with  ECHOPRE 
and  ECHOPOST were considered (Fig.  4). Interestingly, 
LVEF at  ECHOPRE was similar among LV-SUV catego-
ries at any PET scan; consequently, LVEF as measured 
at  ECHOPOST was significantly lower than LVEF at 
 ECHOPRE in patients who had a high LV-SUV at either 
 PETINTERIM or  PETEOT (Fig.  4). In addition, the differ-
ence between LVEF at  ECHOPRE and  ECHOPOST was 
inversely correlated with LV-SUVEOT, the higher being 
LV-SUVEOT the wider the decrease in LVEF (Fig.  5). 
The relation between LV-SUVEOT and the magnitude 
of LVEF change remained significant after adjusting for 
Table 1 Baseline characteristics of  the  patients included 
in the study
RT: radiotherapy;  ECHOPRE: baseline echocardiography; LVEDD: left ventricular 
end-diastolic diameter; LVESD: left ventricular end-systolic diameter; LVEF: left 
ventricular ejection fraction
Male 25 (58%)
Age (years) 35 ± 13
Age > 65 years 0
Hypertension 0
Smoke 18 (42%)
Dyslipidemia 4 (9%)
Family history of heart disease 8 (19%)
Chronic kidney disease 0
Mediastinal RT (non-cardiac field) 6 (14%)
Doxorubicin dose (mg/m2) 251 ± 57
ECHOPRE 26 (60%)
LVEDD (mm) 47.2 ± 5.2
LVESD (mm) 28.2 ± 3.9
LVEF (%) 70.3 ± 7.1
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Fig. 2 18FDG uptake during doxorubicin treatment in the 
myocardium and in the longissimus thoracis muscle. Boxes are 
median and interquartile ranges of left ventricular and skeletal 
muscle 18FDG standardized uptake values (SUV) at the indicated 
18FDG positron emission tomography (18FDG-PET) scans. Vertical bars 
indicate the highest and lowest SUV at each time point. Repeated 
measures ANOVA P for trend = 0.0007 and 0.02 for SUV in the heart 
and longissimus thoracis, respectively. STAGING: 18FDG-PET before 
treatment; INTERIM: 18FDG-PET after 2 cycles of doxorubicin; EOT: 
18FDG-PET at the end of treatment
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age and dose of DOX (univariate analysis: β − 14.5, SE 
4.6, P = 0.004; after accounting for age and DOX dose: β 
− 13.7, SE 4.9, P = 0.01).
By contrast, LVEDD was not significantly different 
among the high and low LV-SUV categories at any PET 
time point (Table 2).
Discussion
The present study shows that DOX-containing chemo-
therapy causes an increase in 18FDG uptake by the nor-
mal heart, as defined by clinical assessment, which is 
associated with a significant decline in LVEF several 
months to years after treatment completion. These 
results substantiate an emerging literature putting 
attention on the effects of anthracyclines on myocardial 
retention of 18FDG-PET [15–17, 19], and raise research 
and practical prospects.
First, our and other authors’ work prompts the ques-
tion of which mechanism underlies the higher accumu-
lation of 18FDG in the myocardium exposed to DOX as 
compared with control conditions. Finding the answer 
would imply gaining insights into the pathogenesis of 
DOX cardiotoxicity, which is complex and still to be fully 
resolved [20], and possibly laying the foundations for 
novel strategies to avoid or mitigate cardiac injury.
DOX and other anthracyclines acutely and invariably 
elicit a triad of alterations in cardiomyocytes—oxidative 
stress, DNA damage due to topoisomerase II poison-
ing and mitochondrial derangement [21]. Intriguingly, 
however, development of gross cardiac abnormalities 
is delayed, in both the animal model and, to the largest 
extent, patients [22, 23]. Therefore, anthracycline car-
diotoxicity may be schematically divided in immediate 
molecular and cellular events, which occur right after 
drug administration, and whole-organ clinically relevant 
perturbations, which most often appear after a temporal 
gap that may last months or even years (Fig. 1). The rea-
son for this two-stage course remains elusive, and several, 
likely not mutually exclusive factors, such as senescence 
[24] or stalled autophagy [14], have been suggested.
Abnormal energy metabolism with depressed mito-
chondrial oxidation and enhanced lactate-producing gly-
colysis characterizes both the early and the late phases of 
anthracycline cardiotoxicity [13, 14, 23] (Fig.  1). Within 
this metabolic reorganization, hexokinase displays 
increased activity [13, 14, 25, 26]. Since this enzyme is 
also thought to be responsible for the phosphorylation 
of 18FDG leading to intracellular tracer retention [27], it 
is conceivable that the augmented myocardial uptake of 
18FDG following DOX chemotherapy is the consequence 
of heightened hexokinase activity. If so, this and other 
recent studies [16, 17, 19, 28] may be viewed as indirect 
confirmation that anthracycline-initiated impairment of 
energy metabolism occurs in the human heart as it does 
in experimental models.
There may be other explanations for cardiac 18FDG 
accumulation upon exposure to DOX. Intracellular medi-
ators other than hexokinase may mediate at least part 
of 18FDG uptake in cardiomyocytes, as it has recently 
been proposed for cancer cells [29]. Furthermore, the 
possible contribution of an increase in the expression of 
transmembrane glucose (and 18FDG) transporters [30], 
as well as of non-cardiomyocytes, must be taken into 
consideration.
Regardless of how the heart becomes more avid of 
18FDG after anthracycline chemotherapy, this phenom-
enon might be exploited for cardiotoxicity surveillance.
Nowadays, LVEF monitoring by repeated echocar-
diography is the standard of care to detect anthracy-
cline cardiotoxicity, but it captures only the late steps of 
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Fig. 3 Left ventricular ejection fraction according to categories of 
18FDG uptake in patients with echocardiography at follow-up. Left 
ventricular ejection fraction (LVEF), as assessed by echocardiography 
performed after completion of anthracycline chemotherapy, in 
patients with myocardial 18FDG standardized uptake values (LV-SUV) 
below or above the median value (low and high, respectively) 
measured at each 18FDG positron emission tomography (18FDG-PET) 
scan. For each PET time point, LVEF was compared between patients 
with LV-SUV below vs. above the median value by unpaired t-test. * 
indicates P < 0.05. LV-SUVSTAGING: LV-SUV at the 18FDG-PET scan before 
treatment; LV-SUVINTERIM: LV-SUV at the 18FDG-PET performed after 2 
cycles of doxorubicin; LV-SUVEOT: LV-SUV at the 18FDG-PET performed 
at the end of chemotherapy
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anthracycline-elicited cardiomyopathy, when global LV 
systolic dysfunction develops. The ideal marker should 
allow the recognition of anthracycline damage much ear-
lier, when cardiac homeostasis is profoundly disrupted 
but the whole heart appears normal. Both troponin, a 
biomarker of cardiomyocyte injury [31], and echocar-
diography with LV global longitudinal strain analysis, 
which identifies an impairment in myocardial deforma-
tion that occurs when LVEF is still preserved, have been 
proposed for the scope [8, 9, 11]. Nevertheless, imple-
mentation of these screening approaches in clinical prac-
tice is difficult, one main reason being that they represent 
further procedures added to the already high number of 
diagnostic tests the oncological patient undergoes, with 
not negligible personal and health care costs.
By contrast, 18FDG-PET offers the unique advantage 
that it is routinely performed for HL [1, 2, 32] and does 
not require additional radiation or exam prolongation. In 
our cohort, higher myocardial 18FDG uptake was associ-
ated with a small but significant drop of LVEF values to 
the very low part of the range of normality, suggesting 
that systematic analysis of radiotracer retention by the 
heart during 18FDG-PET done for oncological purposes 
may be another way to detect anthracycline cardiotox-
icity. Additional work is needed to confirm this oppor-
tunistic use of 18FDG-PET and whether cardiac 18FDG 
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Fig. 4 Left ventricular ejection fraction according to categories of 18FDG uptake in patients with echocardiography at both baseline and follow-up. 
Left ventricular ejection fraction (LVEF) at the baseline and follow-up echocardiography  (LVEFPRE and  LVEFPOST, respectively) in patients with 
myocardial 18FDG standardized uptake values (LV-SUV) below or above the median value (low and high, respectively) at each 18FDG positron 
emission tomography (18FDG-PET) scan. LVEF was compared between patients with LV-SUV below vs. above the median value at each PET time 
point by unpaired t-test and * is P < 0.05.  LVEFPRE and  LVEFPOST for each subgroup of patients with LV-SUV below or above the median value (e.g. 
 LVEFPRE and  LVEFPOST in subjects with high LV-SUV at EOT) were compared by paired t-test; § and # indicate P < 0.05 and < 0.01, respectively. 
LV-SUVSTAGING: LV-SUV at the 18FDG-PET scan before treatment; LV-SUVINTERIM: LV-SUV at the 18FDG-PET performed after 2 cycles of doxorubicin; 
LV-SUVEOT: LV-SUV at the 18FDG-PET performed at the end of chemotherapy
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Fig. 5 Relationship between left ventricular ejection fraction 
change and 18FDG uptake in the subsets of patients with baseline 
and follow-up echocardiography data available. LVEF: left ventricular 
ejection fraction; LV-SUVEOT: LV 18FDG standardized uptake value at 
positron emission tomography performed at the end of anthracycline 
chemotherapy
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accumulation may anticipate LVEF decline, since we did 
not evaluate echocardiograms performed at the same 
time of PET scans. Similarly, it has to be investigated 
whether and how 18FDG-PET can be integrated with 
other imaging techniques and/or circulating biomarkers.
Only a few of our patients had LVEF below the upper 
normal limit and there were no cases of heart failure at 
follow-up. Nonetheless, the study population was made 
of young individuals with low cardiovascular risk, for 
whom minor decreases in LVEF are not expected and 
must be deemed biologically relevant, even though clini-
cally silent. This is even more so considering that such 
patients are generally believed not to be prone to car-
diovascular events and therefore are not monitored in 
this regard. Moreover, it was shown that subjects treated 
with anthracyclines who initially face a small reduction in 
LVEF are at greatest risk of developing heart failure over 
time [18].
There are some limitations of this work to be 
acknowledged. Because of the retrospective design, 
LVEF was calculated from reported LV diameters. 
However, in the presence of normal LV size and 
regional kinesis like for the cases we reviewed, the 
Teicholz formula is reliable to estimate LVEF [7]. Sec-
ond, the 18FDG-PET scans we analyzed were obtained 
without any dietary preparation of the patients, as it is 
routinely done in oncological practice. Even though we 
corrected for SM activity, it cannot be excluded that at 
least part of the variations in myocardial tracer uptake 
were due to different dietary regimens followed by the 
studied subjects. Prospective investigations are needed 
to overcome this shortcoming, by including a high-fat 
low-carbohydrate diet or pharmacological preparation 
to minimize diet-dependent LV-SUV variability. Finally, 
the method used to evaluate myocardial metabolism in 
non-dedicated 18FDG-PET is not yet standardized and 
the LV-SUV thresholds according to which patients 
were categorized were arbitrary. Future studies should 
define the optimal technical aspects and reduce inter-
reader and inter-scanner variability [33].
Conclusions
We propose 18FDG-PET as a tool to better characterize 
and monitor anthracycline toxicity on the human heart, 
with potential clinical implications. Further research 
is warranted to support this claim and expand the evi-
dence from low-risk subjects like the ones we studied 
to a population that ultimately develop heart failure. 
From the basic science standpoint, our results reiterate 
the emphasis on the metabolic aspects of anthracycline 
cardiotoxicity.
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